Last year, Bristol Myers Squibb put a spotlight on the kind of cash that comes with pharma’s conviction in a new oncology ...

Ai3Bio recently emerged from stealth with preclinical programs aimed at what it believes could be a root cause of autoimmune ...

Drugmakers are pouring billions into U.S. production, but building enough plants won’t matter without enough skilled workers ...

Merck is the most exposed to risk from generic competition in the short term, but AbbVie, Johnson & Johnson, Sanofi and ...

Alveus, Lilly, Viking and Amgen are testing maintenance strategies as durability becomes a bigger focus in obesity R&D.

Companies including GSK, Merck, Roche and Sanofi are pushing new approaches in cancer and inflammatory diseases.

Eli Lilly is no stranger to competition from compounded versions of its tirzepatide GLP-1 diabetes and weight loss drugs. But the problem recently took a turn into uncharted territory when medical ...

Roche announced it's building autonomous AI-powered labs; how a clinical hold on an epilepsy trial could impact Biohaven ...

Dr. John Tsai grabbed the reins of global R&D this year with a clear mandate: extend Daiichi’s oncology momentum beyond its ...

The pharma and biotech industries are constantly in flux. Every year, pharma professionals converge on a number of large ...